Zobrazeno 1 - 10
of 175
pro vyhledávání: '"Zhengchao Tu"'
Autor:
Yuanyuan Zhao, Kang Duan, Youlong Fan, Shengrong Li, Liyan Huang, Zhengchao Tu, Hongyan Sun, Gregory M. Cook, Jing Yang, Pinghua Sun, Yi Tan, Ke Ding, Zhengqiu Li
Publikováno v:
Communications Chemistry, Vol 7, Iss 1, Pp 1-16 (2024)
Abstract Covalent probes coupled with chemical proteomics represent a powerful method for investigating small molecule and protein interactions. However, the creation of a reactive warhead within various ligands to form covalent probes has been a maj
Externí odkaz:
https://doaj.org/article/091e321203564c82b8508be17562887f
Autor:
Yuheng Huang, Zhen Wang, Senbiao Fang, Ying Tan, Jiajun Chen, Jiaming Xie, Zhengchao Tu, Weihuan Huang, Ning Li, Haiyan Tian
Publikováno v:
Phytomedicine Plus, Vol 3, Iss 1, Pp 100417- (2023)
Background: Oseltamivir, a neuraminidase inhibitor (NAI), is the primary and first-line anti-influenza drug. In recent years, more and more oseltamivir resistant strains appeared frequently. Purpose: To identify anti-influenza candidates to overcome
Externí odkaz:
https://doaj.org/article/83ddec9f9fdf4c2ab49cb714207ecab4
Autor:
Kaili Jiang, Xia Tang, Jing Guo, Rui He, Shingpan Chan, Xiaojuan Song, Zhengchao Tu, Yuting Wang, Xiaomei Ren, Ke Ding, Zhang Zhang
Publikováno v:
Cancer Medicine, Vol 10, Iss 14, Pp 4874-4884 (2021)
Abstract Abnormallyactivated FGFR1 has been validated as a therapeutic target for differentcancers. Although a variety of FGFR inhibitors have shown benefit in manyclinical patients with FGFR1 aberration, FGFR1 mutant resistance such as V561Mmutation
Externí odkaz:
https://doaj.org/article/db619c6f9e634cc5afe8d264988a6667
Autor:
Yingjun Li, Yongjun Huang, Huimin Cheng, Fang Xu, Ruxi Qi, Botao Dai, Yujian Yang, Zhengchao Tu, Lijie Peng, Zhang Zhang
Publikováno v:
Frontiers in Chemistry, Vol 10 (2022)
The combination of histone deacetylase inhibitor and BRAF inhibitor (BRAFi) has been shown to enhance the antineoplastic effect and reduce the progress of BRAFi resistance. In this study, a series of (thiazol-5-yl)pyrimidin-2-yl)amino)-N-hydroxyalkan
Externí odkaz:
https://doaj.org/article/6a7b82a61177447a944213ed46765845
Autor:
Liang Jiang, Yuting Wang, Qian Li, Zhengchao Tu, Sihua Zhu, Sanfang Tu, Zhang Zhang, Ke Ding, Xiaoyun Lu
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 11, Iss 5, Pp 1315-1328 (2021)
Bcr-Abl threonine 315 to isoleucine 315 (T315I) gatekeeper mutation induced drug resistance remains an unmet clinical challenge for the treatment of chronic myeloid leukemia (CML). Chemical degradation of Bcr-AblT315I protein has become a potential s
Externí odkaz:
https://doaj.org/article/59ba973a56784e7ca3dac5b58fc8567e
Identification of U937JAK3-M511I Acute Myeloid Leukemia Cells as a Sensitive Model to JAK3 Inhibitor
Autor:
Hongfei Si, Jie Wang, Rui He, Xiuwen Yu, Shan Li, Jing Huang, Jie Li, Xia Tang, Xiaojuan Song, Zhengchao Tu, Zhang Zhang, Ke Ding
Publikováno v:
Frontiers in Oncology, Vol 11 (2022)
Mutated JAK3 has been considered a promising target for cancer therapy. Activating mutations of JAK3 are observed in 3.9%–10% of acute myeloid leukemia (AML) patients, but it is unclear whether AML cells are sensitive to JAK3 inhibitors, and no dis
Externí odkaz:
https://doaj.org/article/deac3f4e88db4540967461bdd2acc3b3
Autor:
Jie Wang, Yang Zhou, Xia Tang, Xiuwen Yu, Yongjin Wang, Shingpan Chan, Xiaojuan Song, Zhengchao Tu, Zhimin Zhang, Xiaoyun Lu, Zhang Zhang, Ke Ding
Publikováno v:
Molecules, Vol 27, Iss 19, p 6500 (2022)
The tropomyosin receptor kinases (TRKs) have been validated as effective targets in anticancer drug discovery. Two first-generation TRK inhibitors have been approved into market and displayed an encouraging therapeutic response in cancer patients har
Externí odkaz:
https://doaj.org/article/5d3cba26a0e44ac1a7b99587bb6ed6c7
Autor:
Yuting Wang, Lenghe Zhang, Xia Tang, Jinfeng Luo, Zhengchao Tu, Kaili Jiang, Xiaomei Ren, Fang Xu, Shingpan Chan, Yuhua Li, Zhang Zhang, Ke Ding
Publikováno v:
Translational Oncology, Vol 13, Iss 4, Pp - (2020)
GZD824 is a novel third-generation BCR-ABL inhibitor. It entered Phase II clinical trials in China and Phase Ib clinical trials in USA in 2019 for treatment of patients with resistant chronic myeloid leukemia (CML). We found that at concentrations be
Externí odkaz:
https://doaj.org/article/047a3209e1234e9ab6d6ab4b2e047e8a
Autor:
Zhang Zhang, Jian Zou, Lei Yu, Jinfeng Luo, Yan Li, Zhengchao Tu, Xiaomei Ren, Hongcheng Wei, Liyan Song, Xiaoyun Lu, Ke Ding
Publikováno v:
Cancer Medicine, Vol 7, Iss 4, Pp 1430-1439 (2018)
Abstract YL143 was identified as a novel wild‐type sparing EGFRT790M inhibitor with good pharmacokinetic properties. It potently suppresses EGFRL858R/T790M with an 50% inhibitory concentration (IC50) value of 2.0 ± 0.3 nmol/L, but is approximately
Externí odkaz:
https://doaj.org/article/53478fd73e95458aa9d592c4548abd90
Autor:
Feng Yang, Moses M Njire, Jia Liu, Tian Wu, Bangxing Wang, Tianzhou Liu, Yuanyuan Cao, Zhiyong Liu, Junting Wan, Zhengchao Tu, Yaoju Tan, Shouyong Tan, Tianyu Zhang
Publikováno v:
PLoS ONE, Vol 10, Iss 3, p e0119341 (2015)
In our previous study, we demonstrated that the use of the autoluminescent Mycobacterium tuberculosis as a reporter strain had the potential to drastically reduce the time, effort, animals and costs consumed in evaluation of the activities of drugs a
Externí odkaz:
https://doaj.org/article/42e0c5e6bd8947d3b9f6d281bb0078b7